PSMA-Targeting Amanitin Conjugates with Small Molecule Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current amatoxin conjugates for targeted tumor therapy face challenges with large biomolecule-based targeting moieties, which are costly and difficult to produce, and there is a need for alternative small molecule-based targeting moieties that maintain toxicity and specificity.
Innovation Solution
Conjugation of amatoxins with a PSMA-targeting moiety based on 2-[3-(1,3-dicarboxy-propyl)ureido]pentanedioic acid or 6-amino-2-[3-(1,3-dicarboxypropyl)ureido]-hexanoic acid, linked via a linker and a half-life extension moiety, to create a pharmaceutical composition for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large biomolecule-based targeting moieties (antibodies) are used in amatoxin conjugates, then the conjugates show high specificity and maintained toxicity profile, but the production cost and manufacturing complexity increase significantly
Solution Approach 1:
The patent replaces the original antibody-based targeting moiety with a small molecule PSMA-targeting moiety that copies the targeting function. This small molecule binds to the same PSMA receptor on prostate cancer cells, achieving similar specificity without the manufacturing complexities of antibody production. The small molecule serves as a simplified copy of the antibody's targeting capability.
Solution Approach 2:
The patent employs a small molecule-based targeting moiety instead of an expensive antibody. Small molecules are generally cheaper to produce, more stable, and easier to manufacture at scale. While antibodies have long half-lives, the small molecule is designed to be sufficiently stable for therapeutic use while being more economically viable, embodying the principle of using cheaper alternatives when performance requirements are met.
2Ease of manufacture
If small molecule-based targeting moieties are used instead of large biomolecules, then production cost and manufacturing complexity decrease, but there are serious safety concerns regarding maintained toxicity profile and specificity
Solution Approach 1:
The patent introduces a carefully designed linker as an intermediary between the small molecule PSMA-targeting moiety and the amatoxin cytotoxic payload. This linker is engineered to be stable in circulation to prevent premature toxin release (ensuring specificity) but cleavable inside target cells (releasing the toxin for cytotoxic effect). The linker mediates between the small molecule's stability and the toxin's need for controlled activation.
Solution Approach 2:
The patent optimizes multiple parameters of the small molecule conjugate including the linker length, composition, and cleavage kinetics to achieve the desired balance between stability and specificity. By adjusting these parameters, the conjugate maintains its toxicity profile comparable to antibody-based conjugates while benefiting from small molecule advantages. The PSMA-targeting moiety's binding affinity and selectivity are also fine-tuned to ensure high specificity.
3Reliability
If amatoxin conjugates are designed for targeted tumor therapy, then therapeutic efficacy increases, but the pharmacokinetic half-life may be insufficient without extension moieties
Solution Approach 1:
The patent creates a composite conjugate structure combining four distinct components: the PSMA-targeting small molecule, the linker, the amatoxin cytotoxic payload, and a half-life extension moiety. This composite structure integrates the targeting capability of the small molecule, the controlled delivery mechanism of the linker, the cytotoxic function of amatoxin, and the prolonged circulation time provided by the half-life extension moiety (such as PEG or albumin binding domain), achieving synergistic therapeutic efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.